# Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)

> **NCT05563558** · PHASE2 · RECRUITING · sponsor: **Fundacion Oncosur** · enrollment: 42 (estimated)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Cabazitaxel

## Key facts

- **NCT ID:** NCT05563558
- **Lead sponsor:** Fundacion Oncosur
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-05
- **Primary completion:** 2026-11-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2024-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05563558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05563558, "Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05563558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*